Global

Oncology Experts

Anne-paule Gimenez-roqueplo

Professor
Genetics
Pheochromocytoma and paraganglioma RESearch Support ORganization
Australia

Biography

 Anne-Paule Gimenez-Roqueplo (MD, specialized in Endocrinology, PhD) is Full Professor in the Department of Genetics (Assistance Publique-Hôpitaux de Paris; Hôpital Européen Georges Pompidou) and at Paris Descartes University. She is the leader of an academic research team entitled “Pheochromocytomas and paragangliomas (PCC/PGL), from genetics to molecular targeted therapies” within the INSERM Unit 970 at the Paris Cardiovascular Research Center at HEGP (PARCC@HEGP, Paris, France), which develops a basic, translational and clinical research project dedicated to PCC/PGL Her group established the genetic testing recommendations for patients with PCC/PGL, demonstrated that the identification of a germline SDHB mutation is the first high risk factor of malignancy and of poor prognosis, showed that SDHx-related PCC/PGL are characterized by a stimulation of the hypoxia-angiogenesis pathway and by a hypermethylator phenotype, and published in 2015 the first integrated genomic analysis of a large series of PCC/PGL collected by the COMETE network. Her group develops an integrative genomic approach and different animal and cellular experimental models of malignant PCC/PGL. Her researches are supported by ANR (National Research Agency), the European Union (FP7 & H2020), INCa (National Cancer Institute) and the Ligue Nationale contre le Cancer (National League Against Cancer, ‘Tumor Identity Cards (CIT)’ Programme). She is the past chairman of the Pheochromocytoma-Paraganglioma Research Support Organization (PRESSOR), the head of the Pheochromocytoma working group of the European Network for the Study of Adrenal Tumors (ENS@T) and member of the ENS@T steering committee. She coordinates the COMETE network and the French registry for SDH-related paraganglioma (PGL.R).

Research Interest

Epigenetics Oncology Tumors Genomic Analysis

Publications

  • Rethinking pheochromocytomas and paragangliomas from a genomic perspective.

  • Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.

  • Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.

Global Experts from Australia

Global Experts in Subject

Share This Profile
Recent Expert Updates
  • Matthew L Stone
    Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.   Matthew
    Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone Matthew
    Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone
    Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr. Matthew L Stone
    Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  R Sameh
    Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   R Ismail,
    Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Sameh R Ismail,
    Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   Sameh R Ismail,
    Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   William
    Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America